|Bid||56.75 x 200|
|Ask||59.25 x 100|
|Day's range||57.22 - 59.10|
|52-week range||17.52 - 61.59|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||55.54|
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
Shareholder rights law firm Robbins Arroyo LLP announces that a shareholder derivative complaint was filed on behalf of Juno Therapeutics, Inc. . The complaint is brought against certain current and former officers and directors for alleged breaches of fiduciary duties and unjust enrichment from June 2016 through the present.
Juno Therapeutics, Inc. today announced that it will webcast its presentations at two investor conferences in November. The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development.
Less than a month ago, Evercore ISI analyst Josh Schimmer upgraded Bluebird bio (BLUE) to an Outperform and raised his price target to $152 a share. Today, Schimmer returned to the sidelines on the gene therapy company. As of Friday’s closing bell, Bluebird had closed at $156.25 a share, well above Schimmer’’s previous price target.
Investors may have gotten thrashed owning Celgene stock last month, but there's a lot going on right now that ought to make investors excited.
The clinical-stage biotech is sitting on a large cash stockpile thanks to a third-quarter stock offering and licensing revenue.
Neurocrine Biosciences, Juno Therapeutics and Exelixis topped expectations, though Clovis Oncology lagged.
Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the third quarter 2017.
Juno Therapeutics may still have an advantage that allows it to win market share in what's becoming a competitive market for CAR-T medicine.
Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that 15 abstracts detailing updated clinical and preclinical results from the company and its collaborators will be presented at the 59th American Society of Hematology Annual Meeting.
Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.
Stumbles caused management to trim their outlook, which has some investors wondering if they're going to regret owning shares of the biotech.
Juno Therapeutics, Inc. will announce financial results for the third quarter 2017 on Wednesday, November 1, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 1:30 p.m.
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Juno Therapeutics, Inc. breached their fiduciary duties to shareholders.
Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?
Celgene's partnership strategy gives it exposure to multiple companies' research on next-generation cell therapy.
Adobe Systems skyrocketed overnight on earnings guidance while eBay fell on its outlook. Gilead Sciences rallied on its big FDA win, also lifting Juno Therapeutics.
When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ...